The FDA has approved Eversense 365, a new continuous glucose monitor (CGM) from Senseonics, for people with diabetes who are 18 years of age or older. The Eversense 365 has an implantable CGM sensor ...
CGM use for people with type 2 diabetes led to significant improvements in glucose control and reduced hospitalization. Automated insulin delivery device use was shown to improve time in range, lower ...